Skip to main content

Table 2 Response*(%) at 3 and 6 months, stratified by certolizumab pegol level at 3 months

From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

 OverallCZP < 20 mg/LCZP 20–39.9 mg/LCZP ≥ 40 mg/LOR** (95% CI)P**
 Responders* after 3 months
All patients (n = 245)53%35%65%49%2.3 (1.2–4.5)< 0.05
axSpA (n = 110)40%18%53%37%3.4 (1.0–11.1)< 0.05
RA (n = 81)61%44%74%55%1.5 (0.5–5.1)0.48
PsA (n = 54)69%47%77%77%4.3 (1.0–17.9)< 0.05
 Responders* after 6 months
All patients (n = 245)52%38%63%48%1.9 (1.0–3.5)0.05
axSpA (n = 110)40%18%55%34%3.3 (1.0–10.8)< 0.05
RA (n = 81)57%50%62%55%1.1 (0.3–3.4)0.92
PsA (n = 54)70%53%77%70%3.3 (0.8–13.3)0.09
  1. CZP certolizumab pegol, OR odds ratio, CI confidence interval
  2. *Response in axial spondyloarthritis (axSpA) was defined by clinically important improvement the Ankylosing Spondylitis Disease Activity Score, in rheumatoid arthritis (RA) as European League Against Rheumatism good/moderate response, and in psoriatic arthritis (PsA) as improvement of ≥ 0.6 in 28-joint Disease Activity Score
  3. **Multivariate logistic regression comparing response in patients with CZP < 20 vs ≥ 20 mg/L, adjusting for age, sex and prior biologic disease-modifying antirheumatic drug use (yes/no)